Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2210-2216

  Ananth, Subbian ^b   Knebelmann, Bertrand ^b   Grüning, Wolfram ^b   Dhanabal, Mohanraj ^b   Walz, Gerd ^b   Stillman, Isaac E ^b   Sukhatme, Vikas P ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GENE PRODUCT; MESSENGER RNA; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VON HIPPEL LANDAU GENE PRODUCT; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE REPRESSION; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTIBODIES, MONOCLONAL; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HALF-LIFE; HUMANS; KIDNEY NEOPLASMS; LIGASES; MICE; MICE, MUTANT STRAINS; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; RECOMBINANT FUSION PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; VON WILLEBRAND FACTOR;

EID: 0033135109     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Massague, J., Cheifetz, S., Laiho. M., Ralph, D. A., Weis, F. M., and Zentella, A. Transforming growth factor β. Cancer Surv., 12: 81-103, 1992.
2. Norgaard, P., Hougaard, S., Poulsen, H. S., and Spang-Thomsen, M. Transforming growth factor β and cancer. Cancer Treat. Rev., 21: 367-403, 1995.
3. Huang, F., Newman, E., Theodorescu, D., Kerbel, R. S., and Friedman, E. Transforming growth factor β 1 (TGF β 1 ) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF β 1 antisense expression plasmid. Cell Growth Differ., 6: 1635-1642, 1995.
4. Lu, C., and Kerbel, R. S. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr. Opin. Oncol., 6: 212-220, 1994.
5. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of messenger RNAs for transforming growth factors a and β and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707-712, 1987.
6. Gomella, L. G., Sargent, E. R., Wade, T. P., Anglard, P., Linehan, W. M., and Kasid. A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β 1 in renal cell carcinoma. Cancer Res., 49: 6972-6975, 1989.
7. Ramp, U., Jaquet, K., Reinecke, P., Schardt, C., Friebe, U., Nitsch, T., Marx, N., Gabbert, H. E., and Gerharz, C. D. Functional intactress of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J. Urol., 157: 2345-2350, 1997.
8. MacKay, S. L., Yaswen, L. R., Tamuzzer, R. W., Moldawer, L. L., Bland, K. I., Copeland, E. M. R., and Schultz, G. S. Colon cancer cells that are not growth inhibited by TGF-β lack functional type I and type II TGF-β receptors. Ann. Surg., 221: 767-776, 1995.
9. Jakowlew, S. B., Mathias, A., Chung, P., and Moody, T. W. Expression of transforming growth factor β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ., 6: 465-476, 1995.
10. Jakowlew, S. B., Moody, T. W., and Mariano, J. M. Transforming growth factor-β receptors in human cancer cell lines: analysis of transcript, protein and proliferation. Anticancer Res., 17: 1849-1860, 1997.
11. Norgaard, P., Spang-Thomsen, M., and Poulsen, H. S. Expression and autoregulation of transforming growth factor β receptor mRNA in small-cell lung cancer cell lines. Br. J. Cancer, 73: 1037-1043, 1996.
12. Ramp, U., Jaquet, K., Reinecke, P., Nitsch, T., Gabbert, H. E., and Gerharz, C. D. Acquisition of TGF-β 1 resistance: an important progression factor in human renal cell carcinoma. Lab. Investig., 76: 739-749, 1997.
13. Tsai, J. F., Chuang, L. Y., Jeng, J. E., Yang, M. L., Chang, W. Y., Hsieh, M. Y., Lin, Z. Y., and Tsai, J. H. Clinical relevance of transforming growth factor-β 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltim.), 76: 213-226, 1997.
14. Knoefel, B., Nuske, K., Steiner, T., Junker, K., Kosmehl, H., Rebstock, K., Reinhold, D., and Junker, U. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-β 1 in primary cultures and modulate T lymphocyte blast transformation. J. Interferon Cytokine Res., 17: 95-102, 1997.
15. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., and Geliebter, J. Elevated plasma levels of TGF-β 1 in patients with invasive prostate cancer. Nat. Med., 1: 282-284, 1995.
16. Friess, H., Yamanaka, Y., Buchler, M., Ebert, M., Beger, H. G., Gold, L. I., and Korc, M. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105: 1846-1856, 1993.
17. Junker, U., Knoefel, B., Nuske, K., Rebstock, K., Steiner, T., Wunderlich, H., Junker, K., and Reinhold, D. Transforming growth factor β 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine, 8: 794-798, 1996.
18. Linehan, W. M., Lerman, M. I., and Zbar, B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J. Am. Med. Assoc., 273: 564-570, 1995.
19. Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., and Zhuang, Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol., 149: 2089-2094, 1996.
20. Maher, E. R., and Kaelin, W. G., Jr. von Hippel-Lindau disease. Medicine (Baltim.), 76: 381-391, 1997.
21. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr., and Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA, 93: 10595-10599, 1996.
22. Knebelmann, B., Ananth, S., Cohen, H. T., and Sukhatme, V. P. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res., 58: 226-231, 1998.
23. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S., and Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell Biol., 17: 5629-5639, 1997.
24. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA, 93: 10589-10594, 1996.
25. Pepper, M. S., Mandriota, S. J., Vassalli, J. D., Orci, L., and Montesano, R. Angiogenesis-regulating cytokines: activities and interactions. Curr. Top. Microbiol. Immunol., 213: 31-67, 1996.
26. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W. G., Jr. Tumour suppression by the human von Hippel-Lindau gene product. Natl. Med., 1: 822-826, 1995.
27. Ayala, A., Meldrum, D. R., Perrin, M. M., and Chaudry, I. H. The release of transforming growth factor-β following haemorrhage: its role as a mediator of host immunosuppression. Immunology, 79: 479-484, 1993.
28. Tzai, T. S., Shiau, A. L., Lin, C. S., Wu, C. L., and Lin, J. S. Modulation of the immunostimulating effect of autologous tumor vaccine by anti-TGF-β antibody and interferon-α on murine MBT-2 bladder cancer. Anticancer Res., 17: 1073-1078, 1997.
29. Riser, B. L., Cortes, P., Yee, J., Sharba, A. K., Asano, K., Rodriguez-Barbero, A., and Narins, R. G. Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-β. J. Am. Soc. Nephrol., 9: 827-836, 1998.
30. Cohen, H. T., Bossone, S. A., Zhu, G., McDonald, G. A., and Sukhatme, V. P. Sp1 is a critical regulator of the Wilms' tumor-1 gene. J. Biol. Chem., 272: 2901-2913, 1997.
31. Delahunt, B., Bethwaite, P. B., and Thornton, A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br. J. Urol., 80: 401-404, 1997.
32. Roberts, A. B. Molecular and cell biology of TGF-β. Miner. Electrolyte Metab., 24: 111-119, 1998.
33. Lonergan, K. M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R. C., Conaway, J. W., and Kaelin, W. G., Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol., 18: 732-741, 1998.
34. Pause, A., Lee, S., Worrell, R. A., Chen, D. Y., Burgess, W. H., Linehan, W. M., and Klausner, R. D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA, 94: 2156-2161, 1997.
35. Park, K., Kim, S. J., Bang, Y. J., Park, J. G., Kim, N. K., Roberts, A. B., and Sporn, M. B. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc. Natl. Acad. Sci. USA, 91: 8772-8776, 1994.
36. Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogelstein, B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res., 55: 5548-5550, 1995.
37. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lulterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., and Vogelstein, B. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
38. Lu, S. L., Zhang, W. C., Akiyama, Y., Nomizu, T., and Yuasa, Y. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res., 56: 4595-4598, 1996.
39. Kadin, M. E., Cavaille-Coll, M. W., Gertz, R., Massague, J., Cheifetz, S., and George, D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA, 91: 6002-6006, 1994.
40. Chopra, V., Dinh, T. V., and Hannigan, E. V. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Investig., 16: 152-159, 1998.
41. Steiner, M. S. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol., 153: 1085-1096, 1995.
42. Sehgal, I., Baley, P. A., and Thompson, T. C. Transforming growth factor β 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res., 56: 3359-3365, 1996.
43. Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkami, A. B., Karlsson, S., and Akhurst, R. J. Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knockout mice. Development (Camb.), 121: 1845-1854, 1995.
44. Oshima, M., Oshima, H., and Taketo, M. M. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol., 179: 297-302, 1996.
45. Mandriota, S. J., Menoud, P. A., and Pepper, M. S. Transforming growth factor β 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J. Biol. Chem., 271: 11500-11505, 1996.
46. O'Mahony, C. A., Albo, D., Tuszynski, G. P., and Berger, D. H. Transforming growth factor-β 1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery (St Louis), 124: 388-393, 1998.
47. Ueki, N., Nakazato, M., Ohkawa, T., Ikeda, T., Amuro, Y., Hada, T., and Higashino, K. Excessive production of transforming growth-factor β 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta., 1137: 189-196, 1992.
48. Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., and Forbes, J. T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Investig., 92: 2569-2576, 1993.
49. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
50. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
51. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
52. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, I. E., Lombardo, M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, V. P. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res., 59: 189-197, 1999.
53. Filmus, J., and Kerbel, R. S. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-β during tumor progression. Curr. Opin. Oncol., 5: 123-129, 1993.
54. Fisher, F., and Fisher, E. R. Experimental evidence in support of the dormant tumor cell. Science (Washington DC), 130: 918-919, 1959.
55. Parker, C. C., and Yamold, J. R. Transforming growth factor β: relevance to radiotherapy. Clin. Oncol. (R. Coll. Radiol.), 7: 160-161, 1995.
56. O'Reilly, M. S. Therapeutic implications and mechanisms of angiogenesis. In: IBC Conference, Boston, MA, April 23-24 1998.
57. Santra, M., Skorski, T., Calabretta, B., Lattime, E. C., and Iozzo, R. V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA, 92: 7016-7020, 1995.
58. Huang, S. S., Liu, Q., Johnson, F. E., Konish, Y., and Huang, J. S. Transforming growth factor β peptide antagonists and their conversion to partial agonists. J. Biol. Chem., 272: 27155-27159, 1997.